Krystal Biotech's KB113 Shrinks 83.1% of Assessed Basal Cell Carcinoma Lesions in Gorlin Syndrome Pilot Study
Krystal Biotech reported regression in 83.1% of assessed basal cell carcinoma lesions with KB113 in a three-patient Gorlin syndrome pilot study. Non-injected lesions showed an 85.1% regression rate, providing preliminary evidence of an abscopal effect. Biopsies confirmed complete tumor clearance in one injected lesion